- CHEST Guideline: Antithrombotic therapy for VTE disease [PDF]
- ACC/AHA Task Force on Performance Measures Report: Concepts for Clinician-Patient Shared Accountability in Performance Measures [PDF]
- American Heart Association/American College of Cardiology Foundation Update on Secondary Prevention Lipid Performance Measures
- American Society of Parenteral and Enteral Nutrition (A.S.P.E.N.) Standards of Practice for Nutrition Support Pharmacists
- Antibiotic Resistance Statement from 25 National Health Organizations and the Centers for Disease Control and Prevention [PDF]
- ASHP-ACCP-SCCM-CPG-Critical Care Pharmacy Services: 2020 Update [PDF]
- Camden Coalition's Core Competencies for Front-line Complex Care Providers [PDF]
- Credentialing and Privileging of Pharmacists: A Resource Paper from the Council on Credentialing in Pharmacy (2014)–Council on Credentialing in Pharmacy) AJHP [PDF]
- Code of Ethics for Pharmacists (Reviewed 2012) American Pharmaceutical Association [PDF]
- Definitions of Pharmacy Residencies and Fellowships - Developed by an Ad Hoc Consortium of AACP, ACA, ACCP, APhA, ASCP, ASHP, NARD [PDF]
- Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting [PDF]
- Institute for Healthcare Improvement - No Place Like Home: Advancing the Safety of Care in the Home [PDF]
- Joint Commission of Pharmacy Practitioners Vision for Pharmacists’ Practice [PDF]
- Joint Statement of the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists on Inappropriate Ordering, Prescribing or Dispensing of Medications to Treat COVID-19 [PDF]
- Ketamine Use in Prehospital and Hospital Treatment of the Acute Trauma Patient: A Joint Position Statement - ACS-COT, ACEP, NASEMSO, NAEMSP, and NAEMT [PDF]
- Long-Range Vision for the Pharmacy Work Force in Hospitals and Health Systems (Updated in 2019) – ASHP [PDF]
- National Coordinating Council for Medication Error Reporting and Prevention Recommendations: Statement Opposing the Criminalization of Errors in Healthcare
- National Patient Safety Foundation - RCA2: Improving Root Cause Analyses and Actions to Prevent Harm [PDF]
- Partnership for Health in Aging: Position Statement on Interdisciplinary Team Training in Geriatrics: An Essential Component of Quality Healthcare for Older Adults
- Performance Measures for Adults with Heart Failure (2011) — ACCF/AHA/AMA-PCPI
- Pharmacists’ Patient Care Process – Joint Commission of Pharmacy Practitioners (2014) [PDF]
- Principles for COVID-19 Vaccine Distribution, Allocation, and Mass Immunization (2020) [PDF]
- Principles of a Sound Drug Formulary System (Reviewed 2011) – Endorsed by a Working Group of National Organizations Representing Healthcare [PDF]
- Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-Trace Element Products (2012) – A.S.P.E.N. Position Paper
- Recommendations for Training, Credentialing, and Documenting and Justifying Critical Care Pharmacy Services (2011) Task Force of ACCP, SCCM, ASHP [PDF]
- Report of the ASHP Opioid Task Force [PDF]
- Society for Ambulatory Anesthesia: Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
- Society of Critical Care Medicine Opinion Paper: Outlining Recommendations for Training, Credentialing, Documenting and Justifying Critical Care Pharmacy Services [PDF]
- Society of Hospital Medicine: Making Inpatient Medication Reconciliation Patient Centered, Clinically Relevant, and Implementable: A Consensus Statement on Key Principles and Necessary First Steps [PDF]
- Optimizing the Electronic Health Record in the Parenteral Nutrition Workflow (2018) - ASHP, ASPEN, Academy of Nutrition and Dietetics [PDF]
Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines
CPIC guidelines are designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients’ genotypes available even if they have not explicitly ordered a test with a specific drug in mind. ASHP reviews and endorses select guidelines on an annual basis.
- CPIC Guideline for Fluoropyrimidines and DPYD
- CPIC Guideline for Potent Volatile Anesthetic Agents and Succinylcholine and RYR1 and CACNA1S
- CPIC Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype
- CPIC Guideline for NSAIDs based on CYP2C9 genotype
- CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
- CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
- CPIC Guideline for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
- CPIC Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
- CPIC Guideline for Cytochrome P450-2C19 Genotype and Clopidogrel Therapy
- CPIC Guideline for HLA-B Genotype and Abacavir Dosing
- CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
- CPIC Guideline for CYP3A5 genotype and Tacrolimus Dosing
- CPIC Guideline for Allopurinol and HLA-B
- CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing
- CPIC Guideline for Phenytoin and CYP2C9 and HLA-B
- CPIC Guideline for CYP2C19 and Voriconazole Therapy
- CPIC Guideline for CYP2D6 and Tamoxifen Therapy
- CPIC Guidelines for Ondansetron and Tropisetron based on CYP2D6 genotype
- CPIC Guideline for Aminoglycosides and MT-RNR1
- CPIC Guideline Proton Pump Inhibitors and CYP2C19
- CPIC® Guideline for G6PD
- CPIC® Guideline for HLA genotype and Use of Carbamazepine and Oxcarbazepine
- CPIC® Guideline for Efavirenz based on CYP2B6 genotype
- CPIC® Guideline for Atomoxetine based on CYP2D6 genotype
- CPIC® Guideline for Atazanavir and UGT1A1
